Increased DNA levels in bronchoalveolar lavage fluid obtained from infants with cystic fibrosis

Kevin K. Kirchner, Jeff S. Wagener, Talat Z. Khan, Steven C. Copenhaver, Frank J. Accurso

Research output: Contribution to journalArticle

96 Citations (Scopus)

Abstract

Airway inflammation in children younger than 5 yr of age is difficult to assess, particularly in patients with cystic fibrosis (CF). Furthermore, determining responses to therapies is often subjective in infants, especially those with CF. To determine whether airway DNA levels could be used as an index of airway inflammation, we measured DNA levels in bronchoalveolar lavage fluid (BALF), using a Hoechst dye-binding assay. BALF DNA levels and neutrophils from 16 infants with CF were compared with levels obtained from seven older CF patients and nine control children who underwent bronchoalveolar lavage for evaluation of other pulmonary diseases. BALF DNA was increased in both infants (3.2 ± 0.7 μg/ml) and older patients with CF (5.4 ± 0.9 μg/ml) compared with the controls (0.7 ± 0.2 μg/ml) (mean ± SEM). BALF DNA levels were not significantly different between infants and older patients with CF. BALF neutrophil counts in CF patients were significantly higher than in controls. Furthermore, BALF DNA levels and total neutrophil counts in infants with CF correlated positively with one another. We conclude that: (1) DNA levels were easily quantifiable in BALF of young children; (2) DNA levels in BALF from CF patients were greater than in a group of children with other pulmonary diseases, and that in some infants with CF, BALF DNA levels were equivalent to those of much older patients with CF; (3) DNA levels in BALF correlate with BALF neutrophil number, an index of inflammation; and (4) some infants with CF have increased levels of DNA in BALl:, which may justify a clinical trial of aerosolized rhDNase in this population.

Original languageEnglish (US)
Pages (from-to)1426-1429
Number of pages4
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume154
Issue number5
StatePublished - 1996

Fingerprint

Bronchoalveolar Lavage Fluid
Cystic Fibrosis
DNA
Neutrophils
Inflammation
Lung Diseases
Bronchoalveolar Lavage
Coloring Agents
Clinical Trials

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Increased DNA levels in bronchoalveolar lavage fluid obtained from infants with cystic fibrosis. / Kirchner, Kevin K.; Wagener, Jeff S.; Khan, Talat Z.; Copenhaver, Steven C.; Accurso, Frank J.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 154, No. 5, 1996, p. 1426-1429.

Research output: Contribution to journalArticle

Kirchner, Kevin K. ; Wagener, Jeff S. ; Khan, Talat Z. ; Copenhaver, Steven C. ; Accurso, Frank J. / Increased DNA levels in bronchoalveolar lavage fluid obtained from infants with cystic fibrosis. In: American Journal of Respiratory and Critical Care Medicine. 1996 ; Vol. 154, No. 5. pp. 1426-1429.
@article{897b79a573fb4ba28eb72ba88bf6e400,
title = "Increased DNA levels in bronchoalveolar lavage fluid obtained from infants with cystic fibrosis",
abstract = "Airway inflammation in children younger than 5 yr of age is difficult to assess, particularly in patients with cystic fibrosis (CF). Furthermore, determining responses to therapies is often subjective in infants, especially those with CF. To determine whether airway DNA levels could be used as an index of airway inflammation, we measured DNA levels in bronchoalveolar lavage fluid (BALF), using a Hoechst dye-binding assay. BALF DNA levels and neutrophils from 16 infants with CF were compared with levels obtained from seven older CF patients and nine control children who underwent bronchoalveolar lavage for evaluation of other pulmonary diseases. BALF DNA was increased in both infants (3.2 ± 0.7 μg/ml) and older patients with CF (5.4 ± 0.9 μg/ml) compared with the controls (0.7 ± 0.2 μg/ml) (mean ± SEM). BALF DNA levels were not significantly different between infants and older patients with CF. BALF neutrophil counts in CF patients were significantly higher than in controls. Furthermore, BALF DNA levels and total neutrophil counts in infants with CF correlated positively with one another. We conclude that: (1) DNA levels were easily quantifiable in BALF of young children; (2) DNA levels in BALF from CF patients were greater than in a group of children with other pulmonary diseases, and that in some infants with CF, BALF DNA levels were equivalent to those of much older patients with CF; (3) DNA levels in BALF correlate with BALF neutrophil number, an index of inflammation; and (4) some infants with CF have increased levels of DNA in BALl:, which may justify a clinical trial of aerosolized rhDNase in this population.",
author = "Kirchner, {Kevin K.} and Wagener, {Jeff S.} and Khan, {Talat Z.} and Copenhaver, {Steven C.} and Accurso, {Frank J.}",
year = "1996",
language = "English (US)",
volume = "154",
pages = "1426--1429",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "5",

}

TY - JOUR

T1 - Increased DNA levels in bronchoalveolar lavage fluid obtained from infants with cystic fibrosis

AU - Kirchner, Kevin K.

AU - Wagener, Jeff S.

AU - Khan, Talat Z.

AU - Copenhaver, Steven C.

AU - Accurso, Frank J.

PY - 1996

Y1 - 1996

N2 - Airway inflammation in children younger than 5 yr of age is difficult to assess, particularly in patients with cystic fibrosis (CF). Furthermore, determining responses to therapies is often subjective in infants, especially those with CF. To determine whether airway DNA levels could be used as an index of airway inflammation, we measured DNA levels in bronchoalveolar lavage fluid (BALF), using a Hoechst dye-binding assay. BALF DNA levels and neutrophils from 16 infants with CF were compared with levels obtained from seven older CF patients and nine control children who underwent bronchoalveolar lavage for evaluation of other pulmonary diseases. BALF DNA was increased in both infants (3.2 ± 0.7 μg/ml) and older patients with CF (5.4 ± 0.9 μg/ml) compared with the controls (0.7 ± 0.2 μg/ml) (mean ± SEM). BALF DNA levels were not significantly different between infants and older patients with CF. BALF neutrophil counts in CF patients were significantly higher than in controls. Furthermore, BALF DNA levels and total neutrophil counts in infants with CF correlated positively with one another. We conclude that: (1) DNA levels were easily quantifiable in BALF of young children; (2) DNA levels in BALF from CF patients were greater than in a group of children with other pulmonary diseases, and that in some infants with CF, BALF DNA levels were equivalent to those of much older patients with CF; (3) DNA levels in BALF correlate with BALF neutrophil number, an index of inflammation; and (4) some infants with CF have increased levels of DNA in BALl:, which may justify a clinical trial of aerosolized rhDNase in this population.

AB - Airway inflammation in children younger than 5 yr of age is difficult to assess, particularly in patients with cystic fibrosis (CF). Furthermore, determining responses to therapies is often subjective in infants, especially those with CF. To determine whether airway DNA levels could be used as an index of airway inflammation, we measured DNA levels in bronchoalveolar lavage fluid (BALF), using a Hoechst dye-binding assay. BALF DNA levels and neutrophils from 16 infants with CF were compared with levels obtained from seven older CF patients and nine control children who underwent bronchoalveolar lavage for evaluation of other pulmonary diseases. BALF DNA was increased in both infants (3.2 ± 0.7 μg/ml) and older patients with CF (5.4 ± 0.9 μg/ml) compared with the controls (0.7 ± 0.2 μg/ml) (mean ± SEM). BALF DNA levels were not significantly different between infants and older patients with CF. BALF neutrophil counts in CF patients were significantly higher than in controls. Furthermore, BALF DNA levels and total neutrophil counts in infants with CF correlated positively with one another. We conclude that: (1) DNA levels were easily quantifiable in BALF of young children; (2) DNA levels in BALF from CF patients were greater than in a group of children with other pulmonary diseases, and that in some infants with CF, BALF DNA levels were equivalent to those of much older patients with CF; (3) DNA levels in BALF correlate with BALF neutrophil number, an index of inflammation; and (4) some infants with CF have increased levels of DNA in BALl:, which may justify a clinical trial of aerosolized rhDNase in this population.

UR - http://www.scopus.com/inward/record.url?scp=0029799340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029799340&partnerID=8YFLogxK

M3 - Article

VL - 154

SP - 1426

EP - 1429

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 5

ER -